These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8836663)

  • 1. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial.
    Luisetti M; Sturani C; Sella D; Madonini E; Galavotti V; Bruno G; Peona V; Kucich U; Dagnino G; Rosenbloom J; Starcher B; Grassi C
    Eur Respir J; 1996 Jul; 9(7):1482-6. PubMed ID: 8836663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of MR889, a cyclic thiolic neutrophil elastase inhibitor, on rheologic properties of mucus.
    Moretti M; Gorrini M; Donnetta AM; Baldini EV; Venturini R; Marchioni CF; Iadarola P; Luisetti M
    Life Sci; 1994; 54(7):463-9. PubMed ID: 8309349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound.
    Baici A; Pelloso R; Hörler D
    Biochem Pharmacol; 1990 Mar; 39(5):919-24. PubMed ID: 2310417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of colchicine to reduce the elastase load in the lungs of cigarette smokers with chronic obstructive pulmonary disease.
    Cohen AB; Girard W; Mclarty J; Starcher B; Stevens M; Fair DS; Davis D; James H; Rosenbloom J; Kucich U
    Am Rev Respir Dis; 1990 Jul; 142(1):63-72. PubMed ID: 2195934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of urinary desmosine excretion in patients with chronic obstructive pulmonary disease or cystic fibrosis.
    Bode DC; Pagani ED; Cumiskey WR; von Roemeling R; Hamel L; Silver PJ
    Pulm Pharmacol Ther; 2000; 13(4):175-80. PubMed ID: 10930356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial.
    Dahl R; Titlestad I; Lindqvist A; Wielders P; Wray H; Wang M; Samuelsson V; Mo J; Holt A
    Pulm Pharmacol Ther; 2012 Apr; 25(2):169-77. PubMed ID: 22306193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
    Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA
    COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot clinical trial to determine the safety and efficacy of aerosolized hyaluronan as a treatment for COPD.
    Cantor J; Ma S; Turino G
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2747-2752. PubMed ID: 29075107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy.
    Cantor JO; Ma S; Liu X; Campos MA; Strange C; Stocks JM; Devine MS; El Bayadi SG; Lipchik RJ; Sandhaus RA; Turino GM
    Respir Med; 2021 Jun; 182():106402. PubMed ID: 33906126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of colchicine to reduce the elastase load in the lungs of ex-cigarette smokers with chronic obstructive pulmonary disease.
    Cohen AB; Girard W; Mclarty J; Starcher B; Davis D; Stevens M; Rosenbloom J; Kucich U
    Am Rev Respir Dis; 1991 May; 143(5 Pt 1):1038-43. PubMed ID: 2024812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
    Dal Negro RW; Visconti M; Turco P
    Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM; Beier J; Candler H; Wittig T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
    Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
    Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease.
    Stone PJ; Gottlieb DJ; O'Connor GT; Ciccolella DE; Breuer R; Bryan-Rhadfi J; Shaw HA; Franzblau C; Snider GL
    Am J Respir Crit Care Med; 1995 Apr; 151(4):952-9. PubMed ID: 7697272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desmosine radioimmunoassay for measuring elastin degradation in vivo.
    Harel S; Janoff A; Yu SY; Hurewitz A; Bergofsky EH
    Am Rev Respir Dis; 1980 Nov; 122(5):769-73. PubMed ID: 7447157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
    Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
    Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhalation of LPS induces inflammatory airway responses mimicking characteristics of chronic obstructive pulmonary disease.
    Korsgren M; Linden M; Entwistle N; Cook J; Wollmer P; Andersson M; Larsson B; Greiff L
    Clin Physiol Funct Imaging; 2012 Jan; 32(1):71-9. PubMed ID: 22152082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.